Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Colorectal Neoplasms 13Neoplasms 11Neoplasm Metastasis 11Rectal Neoplasms 6Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Cancer Metastatic 4Colonic Neoplasms 4Carcinoma, Ovarian Epithelial 4Burkitt Lymphoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Prostatic Neoplasms 3Endometrial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uveal Melanoma 2Uterine Cervical Neoplasms 2Testicular Neoplasms 2Stomach Neoplasms 2Sarcoma 2Penile Neoplasms 2

Interventions

Iodine-131 5Sunitinib 3Magnetic Resonance Spectroscopy 3Trastuzumab 2Thyrotropin Alfa 2Gefitinib 2Fluorodeoxyglucose F18 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1pembrolizumab 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1dabrafenib 1cediranib 1aldesleukin 1aflibercept 1X-Rays 1Vorinostat 1Triiodothyronine 1Thalidomide 1Tamoxifen 1Surgical Procedures, Operative 1Semaxinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Follicular × aflibercept × Clear all
NCT00729157 2017-03-15

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 10 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡